Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Baby tamoxifen shows promise in preventing breast cancer recurrence

NCT ID NCT06982313

Prevention Sponsor: Ente Ospedaliero Ospedali Galliera Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows up on women who took a low dose of tamoxifen (5 mg daily) for three years to see if it continues to prevent breast cancer over the long term. The original trial found a 42% reduction in breast cancer events. Researchers will also combine data from three similar studies to get stronger evidence. The goal is to confirm that low-dose tamoxifen is a safe and effective prevention option for women with high-risk breast lesions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tamoxifen (low-dose, 5 mg daily)
What this could lead to
If successful, this could confirm that a low dose of tamoxifen is a safe and effective way to prevent breast cancer in women with high-risk breast changes.
What could go wrong
This is a follow-up study, not a new treatment test. The results may not apply to all women, and long-term side effects are still being monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,545 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 1996

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of all women previously enrolled in the TAM-01 study (EudraCT number: 2007-007740-10), and in the IEO-S007 trial and the prospective cohort study.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Women with DCIS or high-risk lesions or pT1aN0 breast cancer previously enrolled in the TAM-01 trial (EudraCT number: 2007-007740-10) and in the IEO-S007 trial and the prospective cohort study. * Written informed consent. Exclusion criteria: * None.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atypical ductal hyperplasia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast carcinoma breast intraductal proliferative lesion breast neoplasm ductal breast carcinoma in situ lobular breast carcinoma in situ precancerous condition invasive breast carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer invasive

Contacts and locations

Locations

  • Study site

    Genova, Italy, 16145, Italy

  • E. O. Ospedali Galliera

    Genoa, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.